niacinamide and Local Neoplasm Recurrence studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

Excerpt	Relevance	Reference
"To investigate the efficacy and safety of adjuvant sorafenib after curative resection for patients with Barcelona Clinic Liver Cancer (BCLC)-stage C hepatocellular carcinoma (HCC)."	9.22	Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. ( Bie, P; Huan, HB; Lau, WY; Li, XW; Ma, KS; Wen, XD; Wu, LL; Xia, F, 2016)
"Sorafenib, an oral multikinase inhibitor, is the proved therapy method for patients with advanced hepatocellular carcinoma (HCC)."	9.20	Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. ( Han, M; Jing, Y; Kan, X; Liu, KH; Pan, JC; Wan, QY; Wang, Q; Yang, Y; Zhu, M, 2015)
"Currently there is no predictor for survival after adjuvant sorafenib in patients with hepatocellular carcinoma (HCC) who have undergone curative resection."	9.20	Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors. ( Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G, 2015)
"Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation."	9.20	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. ( Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J, 2015)
"The authors assessed the overall response rate, including confirmed complete response (CR) and partial response, in patients with relapsed/refractory multiple myeloma treated with sorafenib."	9.19	A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. ( Barlogie, B; Hoering, A; Hussein, MA; Mazzoni, S; Orlowski, RZ; Popplewell, LL; Sexton, R; Srkalovic, G; Trivedi, H; Zonder, JA, 2014)
"We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect."	9.17	Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. ( Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH, 2013)
" Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them."	9.17	A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013)
"We conducted a phase 2b, randomised, double-blind, placebo-controlled screening trial to evaluate the addition of the multikinase inhibitor sorafenib (antiproliferative/antiangiogenic) to first-line paclitaxel for human epidermal growth factor receptor 2 (HER2)-negative locally recurrent/metastatic breast cancer."	9.17	A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. ( Bondarde, S; Gradishar, WJ; Jain, M; Kaklamani, V; Lokanatha, D; Lokker, NA; Raina, V; Ro, SK; Sahoo, TP; Schwartzberg, L, 2013)
"We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)."	9.17	Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013)
"Between Dec 1, 2006, and July 4, 2008, patients with untreated HER2-negative metastatic breast cancer were randomly assigned (using a randomisation list created by personnel not associated with the study) in a 1:1:1 ratio to paclitaxel (90 mg/m(2) on days 1, 8, and 15 every 3 weeks) plus either masked motesanib 125 mg orally once per day (n=91), masked placebo orally once per day (n=94), or open-label bevacizumab 10 mg/kg intravenously on days 1 and 15 of each 28-day cycle (n=97), after stratification according to adjuvant or neoadjuvant chemotherapy (taxane-containing regimens vs other regimens vs none), number of metastatic sites (<3 vs ≥3), and hormone receptor status (positive vs negative)."	9.15	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. ( Adewoye, H; Adrover, E; Alba, E; Almel, S; Baños, A; Cabaribere, D; Crown, J; Eiermann, W; Hei, YJ; Hurvitz, S; Jagiełło-Gruszfeld, A; Kennedy, MJ; Lang, I; Latreille, J; Lemmerick, Y; Lindsay, MA; Mackey, JR; Martin, M; Moroose, R; Munoz, M; Pienkowski, T; Pinter, T; Priou, F; Provencher, L; Ramos, M; Roche, H; Rolski, J; Rupin, M; Snyder, R, 2011)
"PURPOSE Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with recurrent or metastatic sarcoma."	9.14	Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. ( Antonescu, CR; Blachère, NE; Brockstein, B; Cooney, MM; D'Adamo, DR; Edgar, MA; Elias, AD; Hensley, ML; Keohan, ML; Kraft, AS; Livingston, MB; Maki, RG; Mita, MM; Qin, LX; Saulle, M; Schuetze, SM; Schwartz, GK; Schwartz, LH; Takimoto, CH; Undevia, SD, 2009)
"To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma."	9.14	A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. ( Agamah, E; Elit, L; Fleming, GF; Huo, D; Knost, JA; Morgan, RJ; Nimeiri, HS; Oza, AM; Vokes, EE; Wade, JL, 2010)
"Sorafenib was reported as a useful adjuvant treatment in patients with hepatocellular carcinoma who underwent surgical resection."	9.12	A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. ( Huang, S; Li, D; Sun, L; Wu, J; Zhuang, L, 2021)
"Data on survival and safety of sorafenib for hepatocellular carcinoma recurrence after liver transplant are still equivocal."	8.91	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. ( Belli, L; Cabibbo, G; Cammà, C; Enea, M; Galvano, A; Mancuso, A; Mazzola, A; Perricone, G; Zavaglia, C, 2015)
"Purpose To retrospectively investigate the safety and efficacy of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, TACE-RFA) in the treatment of recurrent hepatocellular carcinoma (rHCC) with portal vein tumor thrombosis, extrahepatic metastases (advanced hepatocellular carcinoma), or both after initial hepatectomy."	7.88	Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. ( Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X, 2018)
"Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC)."	7.83	Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B, 2016)
"Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence."	7.83	Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. ( Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J, 2016)
"To evaluate whether sorafenib use after resection impacts tumor relapse and survival in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC)."	7.83	Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. ( Cai, XB; Hou, Y; Li, J; Liu, B, 2016)
"We investigated the contribution of subsequent therapy for advanced hepatocellular carcinoma refractory or intolerant to sorafenib."	7.83	Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. ( Arai, K; Honda, M; Horii, R; Kaneko, S; Kawaguchi, K; Kitamura, K; Mizukoshi, E; Sakai, Y; Terashima, T; Yamashita, T, 2016)
"Sorafenib improves survival and is superior to the BSC in cases of untreatable posttransplant hepatocellular carcinoma recurrence."	7.83	Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation. ( Azoulay, D; Calderaro, J; Compagnon, P; Costentin, C; de'Angelis, N; Feray, C; Lahat, E; Landi, F; Lim, C; Luciani, A; Nencioni, M; Palen, A; Salloum, C, 2016)
"We explored the hypothesis that sorafenib may improve the effect of transarterial chemoembolization (TACE) in patients with recurrent hepatocellular carcinoma (HCC) and that longer sorafenib duration was associated with additional survival benefits."	7.83	Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. ( Li, J; Shen, F; Wan, X; Wang, K; Wu, D; Xia, Y; Yan, Z; Yang, P; Zhai, X, 2016)
"The aim of this study was to identify the prognostic factors in patients with advanced hepatocellular carcinoma (HCC) who are refractory or intolerant to sorafenib and to exclude unsuitable candidates from subsequent therapy."	7.81	Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib. ( Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Senda, S; Shimizu, S; Takahashi, H, 2015)
"Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC)."	7.81	Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. ( Park, JG, 2015)
" Here, we report a radioiodine-refractory follicular thyroid carcinoma (FTC) patient in whom a notable decrease of MPE was achieved after treatment with sorafenib."	7.80	Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. ( Chen, L; Li, M; Liu, M; Ruan, M; Shen, Y, 2014)
"Sorafenib (SO) was the first targeted agent to produce significant improvements in overall survival in patients with advanced hepatocellular carcinoma (HCC)."	7.79	Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma. ( Moroni, M; Zanlorenzi, L, 2013)
"Retrospective evaluation of the safety and efficacy of sorafenib in patients with post-transplant hepatocellular carcinoma recurrence."	7.78	Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. ( Düber, C; Galle, PR; Heise, M; Hoppe-Lotichius, M; Koch, S; Niederle, IM; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA, 2012)
"We report the use of sorafenib and bevacizumab in combination for a patient with recurrent metastatic hepatoblastoma (HB)."	7.78	Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. ( Cohen, RA; Feusner, JH; Lo, L; Marsh, AM, 2012)
"To evaluate the efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma (HCC) relapse after liver transplantation."	7.78	[Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation]. ( He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Wang, DP; Wang, GD; Wu, LW; Zhu, XF, 2012)
"Sorafenib, a multikinase inhibitor targeting angiogenesis, cell survival, and proliferation in hepatocellular carcinoma (HCC) is a standard therapy for advanced stage disease."	7.77	Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. ( Aucejo, F; Kim, R; Menon, N, 2011)
"Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials."	7.76	Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH, 2010)
"to determine the efficacy and toxicities of sorafenib in the treatment of patients with multiple recurrences of hepatocellular carcinoma (HCC) after liver transplantation in a Chinese population."	7.76	Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. ( FENG, FL; JIANG, XQ; LAU, WY; LIU, C; LUO, XJ; QIU, YH; Qiu, ZQ; RAN, RZ; TAN, WF; WANG, JH; WU, MC; YAN, PN; YI, B; YU, Y; ZHANG, BH, 2010)
"Sorafenib was administered and escalated twice daily on three cohort dose levels: i) 400 mg/day, ii) 600 mg/day and iii) 800 mg/day."	6.78	Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation. ( Carithers, R; Halldorson, J; Jia, N; Lin, EH; Liou, I; Perkins, J; Rao, S; Reyes, J; Stohr, E; Yeh, M, 2013)
" Pharmacokinetic sampling was performed during cycle 1."	6.78	NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ( Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X, 2013)
"Sorafenib was reduced or briefly interrupted in 16 (46%) patients and permanently discontinued in one (3%) case due to toxicity."	6.77	A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. ( Aglietta, M; Asaftei, SD; Casali, PG; D'Ambrosio, L; Dileo, P; Fagioli, F; Ferrari, S; Grignani, G; Mercuri, M; Palmerini, E; Picci, P; Pignochino, Y, 2012)
" The most common severe adverse event probably related to sorafenib was diarrhea (12."	6.77	Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. ( Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M, 2012)
" The maximum tolerated dosage (MTD) for combination therapy was sorafenib 800 mg daily and temsirolimus 25 mg once weekly."	6.77	Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. ( Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK, 2012)
" In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity."	6.76	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011)
"Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems."	6.76	Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ( Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X, 2011)
"The incidence of bladder cancer increases with age, and elderly patients with muscle invasive bladder cancer (MIBC) are significantly undertreated."	5.62	Concurrent carbogen and nicotinamide with radiation therapy in muscle invasive bladder cancer: A report on feasibility in the Australian setting. ( Anzela, A; Azzopardi, M; Barrett, S; Buddle, N; Hooshmand, R; Knesl, M; Min, M; Notman, A; Vignarajah, DD; Wilson, J; Woolls, H, 2021)
"Sorafenib is an oral multi-targeted tyrosine kinase inhibitor used in cases of unresectable advanced HCC that significantly improves progression-free and overall survival."	5.51	[Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib]. ( Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A, 2019)
" Moreover, imetelstat alone and in combination with trastuzumab reduced the CSC fraction and inhibited CSC functional ability, as shown by decreased mammosphere counts and invasive potential."	5.42	The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells. ( Herbert, BS; Koziel, JE, 2015)
"Sorafenib was recently approved for the treatment of these patients."	5.42	Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. ( Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C, 2015)
"Recurrence of hepatocellular carcinoma (HCC) remains a main detriment to long-term survival in liver transplants (LTx) for HCC."	5.40	Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study. ( Alsina, AE; Arrobas, J; Franco, E; Kemmer, N; Makris, A; Nenos, V; Sucre, E, 2014)
"Sorafenib is a molecular-targeted agent which has been demonstrated in two global phase III randomized controlled trials to show survival benefit for advanced HCC."	5.40	Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. ( Bie, P; Huan, HB; Lau, WY; Ma, KS; Xia, F, 2014)
"Adjuvant therapy after resection of hepatocellular carcinoma (HCC) is limited."	5.40	Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. ( Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G, 2014)
"Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) is a rare but challenging condition."	5.39	Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. ( Ganten, TM; Hoffmann, K; Koschny, R; Mehrabi, A; Pfeiffenberger, J; Radeleff, B; Schemmer, P; Schmitz, A; Stremmel, W, 2013)
"Sorafenib treatment for HCC recurrence in transplant recipients represents a challenging oncologic approach that requires further validation in prospective, multicenter studies."	5.38	Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. ( Fouzas, I; Klein, CG; Kykalos, S; Nowak, KW; Paul, A; Sotiropoulos, GC; Vernadakis, S, 2012)
"To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer."	5.38	[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012)
"Sorafenib is a multikinase inhibitor approved for the treatment of advanced HCC."	5.37	Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. ( Aucejo, F; Kim, R, 2011)
"Surgical resection is the first-line treatment for hepatocellular carcinoma (HCC) patients with well-preserved liver function."	5.37	Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. ( Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ, 2011)
"To investigate the efficacy and safety of adjuvant sorafenib after curative resection for patients with Barcelona Clinic Liver Cancer (BCLC)-stage C hepatocellular carcinoma (HCC)."	5.22	Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. ( Bie, P; Huan, HB; Lau, WY; Li, XW; Ma, KS; Wen, XD; Wu, LL; Xia, F, 2016)
"Sorafenib is the first anti-angiogenic agent to demonstrate activity in RMSGC patients, particularly in some histotypes such as HG-MEC, SDC and adenocarcinoma, NOS."	5.22	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. ( Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G, 2016)
"Sorafenib, an oral multikinase inhibitor, is the proved therapy method for patients with advanced hepatocellular carcinoma (HCC)."	5.20	Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. ( Han, M; Jing, Y; Kan, X; Liu, KH; Pan, JC; Wan, QY; Wang, Q; Yang, Y; Zhu, M, 2015)
"Currently there is no predictor for survival after adjuvant sorafenib in patients with hepatocellular carcinoma (HCC) who have undergone curative resection."	5.20	Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors. ( Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G, 2015)
"Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation."	5.20	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. ( Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J, 2015)
"The authors assessed the overall response rate, including confirmed complete response (CR) and partial response, in patients with relapsed/refractory multiple myeloma treated with sorafenib."	5.19	A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. ( Barlogie, B; Hoering, A; Hussein, MA; Mazzoni, S; Orlowski, RZ; Popplewell, LL; Sexton, R; Srkalovic, G; Trivedi, H; Zonder, JA, 2014)
"We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect."	5.17	Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. ( Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH, 2013)
" Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them."	5.17	A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013)
"We conducted a phase 2b, randomised, double-blind, placebo-controlled screening trial to evaluate the addition of the multikinase inhibitor sorafenib (antiproliferative/antiangiogenic) to first-line paclitaxel for human epidermal growth factor receptor 2 (HER2)-negative locally recurrent/metastatic breast cancer."	5.17	A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. ( Bondarde, S; Gradishar, WJ; Jain, M; Kaklamani, V; Lokanatha, D; Lokker, NA; Raina, V; Ro, SK; Sahoo, TP; Schwartzberg, L, 2013)
"We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)."	5.17	Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013)
" In conclusion, sorafenib is active and well tolerated in acute myelogenous leukemia with fms-like tyrosine kinase 3 internal tandem duplication mutation."	5.15	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. ( Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W, 2011)
"Between Dec 1, 2006, and July 4, 2008, patients with untreated HER2-negative metastatic breast cancer were randomly assigned (using a randomisation list created by personnel not associated with the study) in a 1:1:1 ratio to paclitaxel (90 mg/m(2) on days 1, 8, and 15 every 3 weeks) plus either masked motesanib 125 mg orally once per day (n=91), masked placebo orally once per day (n=94), or open-label bevacizumab 10 mg/kg intravenously on days 1 and 15 of each 28-day cycle (n=97), after stratification according to adjuvant or neoadjuvant chemotherapy (taxane-containing regimens vs other regimens vs none), number of metastatic sites (<3 vs ≥3), and hormone receptor status (positive vs negative)."	5.15	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. ( Adewoye, H; Adrover, E; Alba, E; Almel, S; Baños, A; Cabaribere, D; Crown, J; Eiermann, W; Hei, YJ; Hurvitz, S; Jagiełło-Gruszfeld, A; Kennedy, MJ; Lang, I; Latreille, J; Lemmerick, Y; Lindsay, MA; Mackey, JR; Martin, M; Moroose, R; Munoz, M; Pienkowski, T; Pinter, T; Priou, F; Provencher, L; Ramos, M; Roche, H; Rolski, J; Rupin, M; Snyder, R, 2011)
"Between January, 2009 and June, 2011, 10 patients with tumor recurrence after OLT were treated with Sorafenib (group A) and another 8 recipients received no Sorafenib treatment (group B); 25 patients with hepatocellular carcinoma (HCC) also received Sorafenib treatment (group C)."	5.15	[Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients]. ( Li, XH; Liu, Y; Yang, DH; Zhong, KB; Zhou, J, 2011)
"This trial determined the efficacy and tolerability of sorafenib and weekly topotecan in patients with platinum-resistant ovarian cancer (OC) or primary peritoneal carcinomatosis (PPC)."	5.15	Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. ( Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C, 2011)
"PURPOSE Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with recurrent or metastatic sarcoma."	5.14	Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. ( Antonescu, CR; Blachère, NE; Brockstein, B; Cooney, MM; D'Adamo, DR; Edgar, MA; Elias, AD; Hensley, ML; Keohan, ML; Kraft, AS; Livingston, MB; Maki, RG; Mita, MM; Qin, LX; Saulle, M; Schuetze, SM; Schwartz, GK; Schwartz, LH; Takimoto, CH; Undevia, SD, 2009)
"To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma."	5.14	A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. ( Agamah, E; Elit, L; Fleming, GF; Huo, D; Knost, JA; Morgan, RJ; Nimeiri, HS; Oza, AM; Vokes, EE; Wade, JL, 2010)
"Sorafenib was reported as a useful adjuvant treatment in patients with hepatocellular carcinoma who underwent surgical resection."	5.12	A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. ( Huang, S; Li, D; Sun, L; Wu, J; Zhuang, L, 2021)
"Data on survival and safety of sorafenib for hepatocellular carcinoma recurrence after liver transplant are still equivocal."	4.91	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. ( Belli, L; Cabibbo, G; Cammà, C; Enea, M; Galvano, A; Mancuso, A; Mazzola, A; Perricone, G; Zavaglia, C, 2015)
"Liver transplantation (LT) is an established treatment for hepatocellular carcinoma (HCC), and sorafenib (SFN) is a validated treatment for patients harboring advanced tumors."	4.90	Sorafenib use in the transplant setting. ( Burra, P; Castelli, G; Cillo, U; Farinati, F; Giacomin, A; Senzolo, M; Vitale, A, 2014)
"Purpose To retrospectively investigate the safety and efficacy of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, TACE-RFA) in the treatment of recurrent hepatocellular carcinoma (rHCC) with portal vein tumor thrombosis, extrahepatic metastases (advanced hepatocellular carcinoma), or both after initial hepatectomy."	3.88	Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. ( Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X, 2018)
"A 10-year-old boy with FLT3-ITD-positive acute myelogenous leukemia who developed PRES during sorafenib treatment has been presented here."	3.83	Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia. ( Bayhan, T; Cetin, M; Gumruk, F; Isgandarova, F; Kuskonmaz, B; Tavil, B; Unal, S, 2016)
"Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC)."	3.83	Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B, 2016)
"Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence."	3.83	Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. ( Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J, 2016)
"To evaluate whether sorafenib use after resection impacts tumor relapse and survival in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC)."	3.83	Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. ( Cai, XB; Hou, Y; Li, J; Liu, B, 2016)
"We investigated the contribution of subsequent therapy for advanced hepatocellular carcinoma refractory or intolerant to sorafenib."	3.83	Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. ( Arai, K; Honda, M; Horii, R; Kaneko, S; Kawaguchi, K; Kitamura, K; Mizukoshi, E; Sakai, Y; Terashima, T; Yamashita, T, 2016)
"Sorafenib improves survival and is superior to the BSC in cases of untreatable posttransplant hepatocellular carcinoma recurrence."	3.83	Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation. ( Azoulay, D; Calderaro, J; Compagnon, P; Costentin, C; de'Angelis, N; Feray, C; Lahat, E; Landi, F; Lim, C; Luciani, A; Nencioni, M; Palen, A; Salloum, C, 2016)
" We describe a case with progressive recurrent chordoma who initially became hyperthyroid in a context of autoimmunity under sorafenib treatment and later under imatinib treatment."	3.83	Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma. ( Castinetti, F; Eroukhmanoff, J; Penel, N; Salas, S, 2016)
"We explored the hypothesis that sorafenib may improve the effect of transarterial chemoembolization (TACE) in patients with recurrent hepatocellular carcinoma (HCC) and that longer sorafenib duration was associated with additional survival benefits."	3.83	Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. ( Li, J; Shen, F; Wan, X; Wang, K; Wu, D; Xia, Y; Yan, Z; Yang, P; Zhai, X, 2016)
"Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial."	3.83	Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. ( Bouattour, M; de Gramont, A; Faivre, S; Soubrane, O, 2016)
"The aim of this study was to identify the prognostic factors in patients with advanced hepatocellular carcinoma (HCC) who are refractory or intolerant to sorafenib and to exclude unsuitable candidates from subsequent therapy."	3.81	Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib. ( Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Senda, S; Shimizu, S; Takahashi, H, 2015)
" In a study evaluating the combination of sorafenib, bevacizumab, and low-dose cyclophosphamide in children with solid tumors, an unexpectedly high incidence of pneumothorax was observed."	3.81	Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors. ( Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J, 2015)
"Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC)."	3.81	Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. ( Park, JG, 2015)
" Here, we report a radioiodine-refractory follicular thyroid carcinoma (FTC) patient in whom a notable decrease of MPE was achieved after treatment with sorafenib."	3.80	Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. ( Chen, L; Li, M; Liu, M; Ruan, M; Shen, Y, 2014)
" The relative role of such novel radiopharmaceutical versus (131)I scanning of thyroid cancer will require future histopathologic and clinical studies, but it may open new perspectives for presurgical staging of thyroid cancer, and diagnosis of radioiodine negative local relapses and/or distant metastases."	3.80	(99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer. ( Balogh, L; Dierckx, RA; Fremont, V; Galli, F; Manni, I; Piaggio, G; Signore, A; Szkudlinski, MW; Weintraub, BD, 2014)
"Sorafenib (SO) was the first targeted agent to produce significant improvements in overall survival in patients with advanced hepatocellular carcinoma (HCC)."	3.79	Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma. ( Moroni, M; Zanlorenzi, L, 2013)
"Retrospective evaluation of the safety and efficacy of sorafenib in patients with post-transplant hepatocellular carcinoma recurrence."	3.78	Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. ( Düber, C; Galle, PR; Heise, M; Hoppe-Lotichius, M; Koch, S; Niederle, IM; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA, 2012)
"We report the use of sorafenib and bevacizumab in combination for a patient with recurrent metastatic hepatoblastoma (HB)."	3.78	Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. ( Cohen, RA; Feusner, JH; Lo, L; Marsh, AM, 2012)
"To evaluate the efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma (HCC) relapse after liver transplantation."	3.78	[Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation]. ( He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Wang, DP; Wang, GD; Wu, LW; Zhu, XF, 2012)
"Sorafenib, a multikinase inhibitor targeting angiogenesis, cell survival, and proliferation in hepatocellular carcinoma (HCC) is a standard therapy for advanced stage disease."	3.77	Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. ( Aucejo, F; Kim, R; Menon, N, 2011)
"Sorafenib is the only drug that has shown a survival benefit in patients with hepatocellular carcinoma in randomized Phase 3 trials."	3.76	Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH, 2010)
"to determine the efficacy and toxicities of sorafenib in the treatment of patients with multiple recurrences of hepatocellular carcinoma (HCC) after liver transplantation in a Chinese population."	3.76	Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. ( FENG, FL; JIANG, XQ; LAU, WY; LIU, C; LUO, XJ; QIU, YH; Qiu, ZQ; RAN, RZ; TAN, WF; WANG, JH; WU, MC; YAN, PN; YI, B; YU, Y; ZHANG, BH, 2010)
"We identified 12 cases: 5 CRs with sunitinib, 1 CR with sorafenib, and 6 surgical CRs with sunitinib followed by residual metastasectomy."	3.75	Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. ( Bex, A; Cosentino, M; Ficarra, V; Flörcken, A; Grünwald, V; Johannsen, M; Kloeters, C; Miller, K; Rief, M; Rogalla, P; Roigas, J, 2009)
"Subcutaneous tumours and artificially induced pulmonary metastases of the rhabdomyosarcoma R1H of the rat were treated either with fractionated irradiation alone or in combination with nicotinamide and carbogen."	3.69	Combination of fractionated irradiation with nicotinamide and carbogen in R1H-tumours of the rat and its pulmonary metastases. ( Beck-Bornholdt, HP; Krüll, A; Raabe, A; Rett, M, 1997)
"Sorafenib was administered orally at 400 mg bid on a continuous basis."	2.82	Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. ( Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M, 2016)
"This study was designed to evaluate the response and toxicity of sorafenib alone or when combined with carboplatin and paclitaxel in patients with platinum-sensitive, recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (EOC)."	2.79	Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. ( Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ, 2014)
"Forty-three acute myeloid leukemia (AML) patients with a median age of 64 years (range, 24-87 years) were enrolled; 37 were evaluable for response."	2.78	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. ( Alattar, ML; Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Dellasala, S; Faderl, S; Garcia-Manero, G; Grunwald, MR; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Pierce, S; Rajkhowa, T; Ravandi, F; Richie, MA; Rudek, MA, 2013)
"Sorafenib was administered and escalated twice daily on three cohort dose levels: i) 400 mg/day, ii) 600 mg/day and iii) 800 mg/day."	2.78	Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation. ( Carithers, R; Halldorson, J; Jia, N; Lin, EH; Liou, I; Perkins, J; Rao, S; Reyes, J; Stohr, E; Yeh, M, 2013)
" Pharmacokinetic sampling was performed during cycle 1."	2.78	NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ( Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X, 2013)
"Sorafenib was reduced or briefly interrupted in 16 (46%) patients and permanently discontinued in one (3%) case due to toxicity."	2.77	A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. ( Aglietta, M; Asaftei, SD; Casali, PG; D'Ambrosio, L; Dileo, P; Fagioli, F; Ferrari, S; Grignani, G; Mercuri, M; Palmerini, E; Picci, P; Pignochino, Y, 2012)
" The most common severe adverse event probably related to sorafenib was diarrhea (12."	2.77	Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. ( Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M, 2012)
" The maximum tolerated dosage (MTD) for combination therapy was sorafenib 800 mg daily and temsirolimus 25 mg once weekly."	2.77	Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. ( Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK, 2012)
" In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity."	2.76	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011)
"Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems."	2.76	Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ( Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X, 2011)
"The overall incidence of brain metastases in patients receiving sorafenib was 3% (2 of 70 patients) compared with 12% (8 of 69 patients) in patients receiving placebo (P < 0."	2.75	Incidence of brain metastases in renal cell carcinoma treated with sorafenib. ( Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Szczylik, C; Zonierek, J, 2010)
"Gemcitabine has known activity against EOC."	2.75	Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. ( Elit, L; Hirte, HW; Macalpine, K; Oza, AM; Schilder, RJ; Wang, L; Welch, SA; Wright, JJ, 2010)
"Sorafenib is a multikinase inhibitor affecting pathways involved in tumor progression and angiogenesis."	2.75	Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. ( Bury, MJ; Floyd, JD; Gandara, DR; Gitlitz, BJ; Glisson, BS; Ho, C; Moon, J; Reimers, HJ; Schulz, TK; Sundaram, PK, 2010)
"Sorafenib is an oral multikinase inhibitor that targets the Ras/Raf/MEK/ERK mitogenic signaling pathway and the angiogenic receptor tyrosine kinases, vascular endothelial growth factor receptor 2 and platelet-derived growth factor receptor beta."	2.74	Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. ( Blumenschein, GR; Cihon, F; Cupit, L; Fossella, F; Gatzemeier, U; O'Leary, J; Reck, M; Stewart, DJ, 2009)
" Potential drug-drug interactions and the relationship between pharmacokinetics and toxicity were also assessed."	2.73	Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. ( Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C, 2007)
"Sorafenib was well tolerated with few grade 3 and no grade 4 toxicities."	2.73	Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. ( Agulnik, M; Cheiken, R; Chen, EX; Chin, SF; Elser, C; Elting, J; Francis, P; McNabola, A; Petrenciuc, O; Pond, GR; Siu, LL; Wilkie, D; Winquist, E, 2007)
" Sorafenib demonstrated single-agent activity in Phase I studies, and was tolerated and inhibited tumor growth in combination with doxorubicin in preclinical studies."	2.72	Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. ( Brendel, E; Christensen, O; Flashar, C; Grubert, M; Henning, BF; Hilger, RA; Kupsch, P; Ludwig, M; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R, 2006)
"In western countries, hepatocellular carcinoma (HCC) is a major reason for orthotopic liver transplantation (OLT) with estimated recurrence rates between 15% and 20%."	2.49	Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. ( Bechstein, WO; Trojan, J; Welker, MW; Zeuzem, S, 2013)
"The prognosis of pulmonary blastoma is very poor; overall five-year survival is 16%."	2.47	Classic biphasic pulmonary blastoma: a case report and review of the literature. ( Boeykens, E; Rutsaert, R; Stappaerts, I; Van Loo, S, 2011)
"It is widely accepted that hepatocellular carcinoma (HCC) has an annual recurrence rate of approximately 15-20% even after potentially curative treatment, with the 5-year recurrence rate reaching 80-90%."	2.47	Adjuvant therapy after curative treatment for hepatocellular carcinoma. ( Kudo, M, 2011)
"The incidence of bladder cancer increases with age, and elderly patients with muscle invasive bladder cancer (MIBC) are significantly undertreated."	1.62	Concurrent carbogen and nicotinamide with radiation therapy in muscle invasive bladder cancer: A report on feasibility in the Australian setting. ( Anzela, A; Azzopardi, M; Barrett, S; Buddle, N; Hooshmand, R; Knesl, M; Min, M; Notman, A; Vignarajah, DD; Wilson, J; Woolls, H, 2021)
"Sorafenib is an oral multi-targeted tyrosine kinase inhibitor used in cases of unresectable advanced HCC that significantly improves progression-free and overall survival."	1.51	[Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib]. ( Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A, 2019)
"Treatment of unresectable recurrent hepatocellular carcinoma (HCC) in patients who recur after resection or orthotopic liver transplantation (OLT) remains a clinical challenge."	1.46	Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry. ( Babajanyan, S; Bruenderman, E; Cohn, A; Foreman, P; Geschwind, JF; Gholam, P; Goldenberg, A; Mantry, P; Martin, RC; McGuire, B; Miksad, R; Piperdi, B; Sanyal, A; Zigmont, E, 2017)
"Their hematological malignancies were well-controlled at the time of liver resection."	1.46	Liver resection for hepatocellular carcinoma in patients with hematological malignancies. ( Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS, 2017)
"Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors."	1.43	(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. ( Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T, 2016)
"To evaluated patterns and outcomes of hepatocellular carcinoma (HCC) recurrence after living donor liver transplantation (LDLT)."	1.43	Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation. ( Hong, TH; Kim, DG; Na, GH; You, YK, 2016)
"Late recurrence of renal cell carcinoma is not a rare event."	1.42	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. ( Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E, 2015)
"In head and neck squamous cell carcinoma (HNSCC), the role of sprouty2 in tumorigenesis and clinical implication remains elusive."	1.42	Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. ( Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL, 2015)
" Moreover, imetelstat alone and in combination with trastuzumab reduced the CSC fraction and inhibited CSC functional ability, as shown by decreased mammosphere counts and invasive potential."	1.42	The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells. ( Herbert, BS; Koziel, JE, 2015)
"Sorafenib was recently approved for the treatment of these patients."	1.42	Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. ( Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C, 2015)
"Sorafenib is an oral multikinase inhibitor targeting Raf and other kinases."	1.40	Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. ( Baba, T; Konishi, I; Koshiyama, M; Matsumura, N; Yamaguchi, K; Yoshioka, Y, 2014)
"Sorafenib (Nexavar) is a multi-kinase inhibitor that was developed as an inhibitor of RAF-1, in the ERK1/2 pathway, but which was subsequently shown to inhibit class III tyrosine kinase receptors."	1.40	Multi-kinase inhibition in ovarian cancer. ( Dent, P, 2014)
"Hepatocellular carcinoma is a major cause of death among patients with cirrhosis."	1.40	Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. ( Behnke, M; Bornstein, K; Cotterell, A; Fisher, RA; Fulcher, A; Lee, DD; Posner, MP; Ramanathan, R; Sharma, A; Stravitz, RT; Sydnor, M, 2014)
"Recurrence of hepatocellular carcinoma (HCC) remains a main detriment to long-term survival in liver transplants (LTx) for HCC."	1.40	Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study. ( Alsina, AE; Arrobas, J; Franco, E; Kemmer, N; Makris, A; Nenos, V; Sucre, E, 2014)
"Pediatric ependymomas are highly recurrent tumors resistant to conventional chemotherapy."	1.40	Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. ( Adamski, J; Agnihotri, S; Barszczyk, M; Buczkowicz, P; Castelo-Branco, P; Dirks, PB; Elizabeth, C; Golbourn, B; Hawkins, C; Li, XN; Luu, B; Mack, SC; Mangerel, J; Morrison, A; Nethery-Brokx, K; Pajovic, S; Ramaswamy, V; Remke, M; Rutka, JT; Tabori, U; Taylor, MD; Van Meter, T; Yu, M, 2014)
"Sorafenib is a molecular-targeted agent which has been demonstrated in two global phase III randomized controlled trials to show survival benefit for advanced HCC."	1.40	Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. ( Bie, P; Huan, HB; Lau, WY; Ma, KS; Xia, F, 2014)
"Adjuvant therapy after resection of hepatocellular carcinoma (HCC) is limited."	1.40	Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. ( Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G, 2014)
"Recurrence and chemoresistance of liver cancer has been attributed to the existence of liver tumor-initiating cells (T-ICs)."	1.39	Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling. ( Cao, D; Chen, C; Chen, SZ; Ding, J; Feng, GS; Han, T; Huang, L; Sun, W; Tang, L; Wang, HY; Wang, X; Wen, W; Wu, MC; Xiang, DM, 2013)
"Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) is a rare but challenging condition."	1.39	Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. ( Ganten, TM; Hoffmann, K; Koschny, R; Mehrabi, A; Pfeiffenberger, J; Radeleff, B; Schemmer, P; Schmitz, A; Stremmel, W, 2013)
"Sorafenib treatment for HCC recurrence in transplant recipients represents a challenging oncologic approach that requires further validation in prospective, multicenter studies."	1.38	Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. ( Fouzas, I; Klein, CG; Kykalos, S; Nowak, KW; Paul, A; Sotiropoulos, GC; Vernadakis, S, 2012)
"To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer."	1.38	[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012)
"Sorafenib is a multikinase inhibitor approved for the treatment of advanced HCC."	1.37	Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. ( Aucejo, F; Kim, R, 2011)
"Surgical resection is the first-line treatment for hepatocellular carcinoma (HCC) patients with well-preserved liver function."	1.37	Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. ( Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ, 2011)
"Sorafenib is a multikinase inhibitor approved for the treatment of renal cell carcinoma and hepatocellular carcinoma."	1.37	[Squamous cell carcinoma in a patient receiving sorafenib]. ( Adnot-Desanlis, L; Bernard, P; Reguiaï, Z, 2011)

Research

Studies (174)

Authors

Clinical Trials (26)

Trial Overview

Trial Outcomes

5-year Disease-free Survival (DFS) Rate Among Patients With Clear Cell Histology

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (1.72)	18.2507
2000's	16 (9.20)	29.6817
2010's	146 (83.91)	24.3611
2020's	9 (5.17)	2.80

Authors	Studies
Alberts, I	2
Mingels, C	1
Zacho, HD	1
Lanz, S	1
Schöder, H	1
Rominger, A	2
Zwahlen, M	1
Afshar-Oromieh, A	2
Lengana, T	1
Lawal, I	1
Janse Van Rensburg, C	1
Mokoala, K	1
Moshokoa, E	1
Mazibuko, S	1
Van de Wiele, C	1
Maes, A	1
Vorster, M	1
Sathekge, MM	1
Kisiel, N	1
Thomas, P	1
Bütikofer, L	1
Witkowska-Patena, E	2
Giżewska, A	2
Dziuk, M	2
Miśko, J	2
Budzyńska, A	1
Walęcka-Mazur, A	1
Arend, RC	1
Davis, AM	1
Chimiczewski, P	1
O'Malley, DM	1
Provencher, D	1
Vergote, I	1
Ghamande, S	1
Birrer, MJ	2
Watabe, T	1
Uemura, M	1
Soeda, F	1
Naka, S	1
Ujike, T	1
Hatano, K	1
Sasaki, H	1
Kamiya, T	1
Shimosegawa, E	1
Kato, H	1
Cardinale, J	2
Tateishi, U	1
Nonomura, N	1
Giesel, FL	4
Huang, S	1
Li, D	1
Zhuang, L	1
Sun, L	1
Wu, J	2
Anzela, A	1
Min, M	1
Knesl, M	1
Buddle, N	1
Azzopardi, M	1
Hooshmand, R	1
Barrett, S	1
Notman, A	1
Woolls, H	1
Wilson, J	1
Vignarajah, DD	1
Martin, RC	1
Bruenderman, E	1
Cohn, A	1
Piperdi, B	1
Miksad, R	1
Geschwind, JF	1
Goldenberg, A	1
Sanyal, A	1
Zigmont, E	1
Babajanyan, S	1
Foreman, P	1
Mantry, P	1
McGuire, B	1
Gholam, P	1
Sarosiek, K	1
Ohki, T	1
Kondo, M	1
Karasawa, Y	1
Kawamura, S	1
Maeshima, S	1
Kojima, K	1
Seki, M	1
Toda, N	1
Shioda, Y	1
Tagawa, K	1
Mancuso, A	5
Maringhini, A	1
Song, W	1
Hwang, Y	1
Youngblood, VM	1
Cook, RS	1
Balko, JM	1
Chen, J	1
Brantley-Sieders, DM	1
Benech, N	1
Walter, T	1
Saurin, JC	1
Li, G	1
Mu, X	1
Huang, X	2
Qian, X	1
Qin, J	1
Tan, Z	1
Zhang, W	5
Xu, X	1
Tan, S	1
Zhu, Z	1
Li, W	1
Wang, X	4
Sun, B	1
Guerrini, GP	1
Berretta, M	1
Tarantino, G	1
Magistri, P	1
Pecchi, A	1
Ballarin, R	1
Di Benedetto, F	1
Kubota, K	1
Yoshioka, H	1
Oshita, F	1
Hida, T	1
Yoh, K	1
Hayashi, H	1
Kato, T	1
Kaneda, H	1
Yamada, K	1
Tanaka, H	1
Ichinose, Y	1
Park, K	1
Cho, EK	1
Lee, KH	1
Lin, CB	1
Yang, JC	1
Hara, K	1
Asato, T	1
Nakagawa, K	1
Buti, S	2
Puligandla, M	1
Bersanelli, M	1
DiPaola, RS	1
Manola, J	1
Taguchi, S	1
Haas, NB	1
Hiraoka, A	1
Kumada, T	1
Kudo, M	3
Hirooka, M	1
Koizumi, Y	1
Hiasa, Y	1
Tajiri, K	1
Toyoda, H	1
Tada, T	1
Ochi, H	1
Joko, K	1
Shimada, N	1
Deguchi, A	1
Ishikawa, T	1
Imai, M	1
Tsuji, K	1
Michitaka, K	1
Lin, HC	1
Yang, YS	1
Teng, CJ	1
Shen, CH	1
Jan, YG	1
Cheng, SB	1
Wu, CC	1
Lin, YL	1
Huang, CC	1
P'eng, FK	1
Paddubny, K	2
Freitag, MT	1
Kratochwil, C	3
Koerber, S	1
Radtke, JP	2
Sakovich, R	1
Kopka, K	3
Will, L	1
Kremer, C	1
Rathke, H	1
Haufe, S	1
Haberkorn, U	2
Peng, Z	1
Chen, S	1
Wei, M	1
Lin, M	1
Jiang, C	1
Mei, J	1
Li, B	2
Wang, Y	2
Li, J	4
Xie, X	1
Chen, M	1
Qian, G	1
Kuang, M	1
Rahbar, K	2
Weckesser, M	2
Ahmadzadehfar, H	1
Schäfers, M	1
Stegger, L	1
Bögemann, M	2
Seifert, R	1
Schafigh, D	1
Takeda, Y	1
Ohmura, Y	1
Katsura, Y	1
Sakamoto, T	1
Nose, Y	1
Mori, R	1
Inatome, J	1
Kawai, K	1
Naito, A	1
Murakami, K	1
Kagawa, Y	1
Masuzawa, T	1
Takeno, A	1
Egawa, C	1
Murata, K	1
Yan, J	1
Tan, C	1
Gu, F	1
Jiang, J	1
Xu, M	1
Dai, Z	2
Wang, Z	2
Fan, J	2
Zhou, J	3
Xia, H	1
Ooi, LL	1
Hui, KM	1
Sposito, C	4
Mariani, L	2
Germini, A	2
Flores Reyes, M	1
Bongini, M	1
Grossi, G	1
Bhoori, S	2
Mazzaferro, V	6
Toso, C	1
Mentha, G	1
Majno, P	1
Ravandi, F	2
Alattar, ML	1
Grunwald, MR	1
Rudek, MA	1
Rajkhowa, T	1
Richie, MA	1
Pierce, S	1
Daver, N	1
Garcia-Manero, G	1
Faderl, S	2
Nazha, A	1
Konopleva, M	2
Borthakur, G	2
Burger, J	1
Kadia, T	1
Dellasala, S	1
Andreeff, M	2
Cortes, J	1
Kantarjian, H	2
Levis, M	1
Jia, N	1
Liou, I	1
Halldorson, J	1
Carithers, R	1
Perkins, J	1
Reyes, J	1
Yeh, M	1
Stohr, E	1
Rao, S	1
Lin, EH	1
Wen, W	1
Han, T	1
Chen, C	1
Huang, L	1
Sun, W	1
Chen, SZ	1
Xiang, DM	1
Tang, L	1
Cao, D	1
Feng, GS	1
Wu, MC	3
Ding, J	1
Wang, HY	2
Greenwald, DR	1
Li, H	3
Luger, SM	1
Go, RS	1
King, D	1
Patel, T	1
Gascoyne, RD	1
Kolesar, J	1
Kahl, BS	1
Horning, S	1
Galanis, E	1
Anderson, SK	1
Lafky, JM	1
Uhm, JH	1
Giannini, C	1
Kumar, SK	1
Kimlinger, TK	1
Northfelt, DW	1
Flynn, PJ	1
Jaeckle, KA	1
Kaufmann, TJ	1
Buckner, JC	1
Moroni, M	1
Zanlorenzi, L	1
Yoshinaga, A	1
Ichiyanagi, N	1
Kamata, S	1
Felga, G	1
Salvalaggio, PR	1
de Rezende, MB	1
de Almeida, MD	1
Pfeiffenberger, J	1
Koschny, R	1
Hoffmann, K	1
Mehrabi, A	1
Schmitz, A	1
Radeleff, B	1
Stremmel, W	1
Schemmer, P	1
Ganten, TM	1
Koshiyama, M	1
Matsumura, N	1
Baba, T	1
Yamaguchi, K	1
Yoshioka, Y	1
Konishi, I	1
Thompson, PA	1
Drissi, R	2
Muscal, JA	1
Panditharatna, E	1
Fouladi, M	2
Ingle, AM	1
Ahern, CH	1
Reid, JM	1
Lin, T	2
Weigel, BJ	1
Blaney, SM	1
Fontanelli, G	1
Rocco, M	1
Caracciolo, F	1
Benedetti, E	1
Buda, G	1
Orciuolo, E	1
Carulli, G	1
Galimberti, S	1
Azzarà, A	1
Petrini, M	1
Mazzarelli, C	2
Perricone, G	3
Zavaglia, C	3
Dent, P	1
Chen, K	1
Man, K	1
Metselaar, HJ	1
Janssen, HL	1
Peppelenbosch, MP	1
Pan, Q	1
Hassler, MR	1
Ackerl, M	1
Flechl, B	1
Sax, C	1
Wöhrer, A	1
Widhalm, G	1
Dieckmann, K	1
Hainfellner, J	1
Preusser, M	1
Marosi, C	1
Ramanathan, R	1
Sharma, A	1
Lee, DD	1
Behnke, M	1
Bornstein, K	1
Stravitz, RT	1
Sydnor, M	1
Fulcher, A	1
Cotterell, A	1
Posner, MP	1
Fisher, RA	1
Bruix, J	2
Gores, GJ	1
Schwandt, A	1
von Gruenigen, VE	1
Wenham, RM	2
Frasure, H	1
Eaton, S	1
Fusco, N	1
Fu, P	1
Wright, JJ	4
Dowlati, A	1
Waggoner, S	1
Liu, M	1
Shen, Y	1
Ruan, M	1
Li, M	1
Chen, L	1
Belli, LS	1
Galli, F	1
Manni, I	1
Piaggio, G	1
Balogh, L	1
Weintraub, BD	1
Szkudlinski, MW	1
Fremont, V	1
Dierckx, RA	1
Signore, A	1
Castelli, G	1
Burra, P	1
Giacomin, A	1
Vitale, A	2
Senzolo, M	1
Cillo, U	2
Farinati, F	1
Bambury, RM	1
Morris, PG	1
Gibson, JF	1
Foss, F	1
Cooper, D	1
Seropian, S	1
Irizarry, D	1
Barbarotta, L	1
Lansigan, F	1
Srkalovic, G	1
Hussein, MA	1
Hoering, A	1
Zonder, JA	1
Popplewell, LL	1
Trivedi, H	1
Mazzoni, S	1
Sexton, R	1
Orlowski, RZ	1
Barlogie, B	1
Alsina, AE	1
Makris, A	1
Nenos, V	1
Sucre, E	1
Arrobas, J	1
Franco, E	1
Kemmer, N	1
Santoni, M	1
Conti, A	1
Porta, C	1
Procopio, G	1
Sternberg, CN	1
Basso, U	1
De Giorgi, U	1
Bracarda, S	1
Rizzo, M	1
Ortega, C	1
Massari, F	1
Iacovelli, R	1
Derosa, L	1
Masini, C	1
Milella, M	1
Di Lorenzo, G	1
Atzori, F	1
Pagano, M	1
De Vivo, R	1
Mosca, A	1
Rossi, M	1
Paglino, C	1
Verzoni, E	1
Cerbone, L	1
Muzzonigro, G	1
Falconi, M	1
Montironi, R	1
Burattini, L	1
Santini, D	1
Cascinu, S	1
Barszczyk, M	1
Buczkowicz, P	1
Castelo-Branco, P	1
Mack, SC	1
Ramaswamy, V	1
Mangerel, J	1
Agnihotri, S	1
Remke, M	2
Golbourn, B	1
Pajovic, S	1
Elizabeth, C	1
Yu, M	1
Luu, B	1
Morrison, A	1
Adamski, J	1
Nethery-Brokx, K	1
Li, XN	1
Van Meter, T	1
Dirks, PB	1
Rutka, JT	1
Taylor, MD	1
Tabori, U	1
Hawkins, C	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 for the Detection of Recurrent Prostate Cancer in PSMA-ligand PET/CT[NCT05079828]		100 participants (Anticipated)	Interventional	2022-07-07	Recruiting
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma[NCT00326898]	Phase 3	1,943 participants (Actual)	Interventional	2006-04-24	Completed
Phase I/II Study of Sorafenib and 5-Azacitidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS) - (VZ-MDS-PI-0227)[NCT01254890]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2011-01-31	Completed
Transarterial Chemoembolization With Lipiodol-Idarubicin Emulsion in the Treatment of Hepatocellular Carcinoma: a Prospective, Multicenter, Real-world Study[NCT05280444]	Phase 2/Phase 3	216 participants (Anticipated)	Interventional	2022-05-28	Recruiting
Biomarker Analyses in Hepatocellular Carcinoma Patients Treated With Therasphere®[NCT03203837]		4 participants (Actual)	Observational	2017-07-05	Terminated (stopped due to Funding Discontinued due to low accrual rate)
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma：a Randomized, Open-label, Parallel, Multicenter Trial[NCT04521153]		290 participants (Anticipated)	Interventional	2021-03-25	Recruiting
The Clinical Randomized Trial of Adjuvant Chemotherapy With FOLFOX in HCC Patients at High Risk After Resection[NCT02738697]	Phase 3	290 participants (Anticipated)	Interventional	2016-01-31	Recruiting
A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.[NCT00692770]	Phase 3	1,114 participants (Actual)	Interventional	2008-08-15	Completed
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation in Curative Intent: French Multicenter Phase 2 Therapeutic[NCT06045975]	Phase 2	30 participants (Anticipated)	Interventional	2023-12-04	Not yet recruiting
Adjuvant Tislelizumab With or Without Lenvatinib for Patients at High-risk of Hepatocellular Carcinoma Recurrence After Curative Resection or Ablation: a Multicentric, Prospective Study[NCT05910970]	Phase 3	200 participants (Anticipated)	Interventional	2023-08-30	Not yet recruiting
Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial[NCT02767375]	Phase 2/Phase 3	192 participants (Anticipated)	Interventional	2015-02-28	Recruiting
A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304]		52 participants (Actual)	Interventional	2016-04-30	Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.)
Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143]	Phase 2	30 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
Lenvatinib in Neo-adjuvant and Adjuvant Therapy for Poor-prognosis BCLC A HepatoCellular Carcinoma Treated by Percutaneous Ablation Procedure in a Curative Intent: Multicentre Pilot Therapeutic Trial[NCT05113186]	Phase 2	50 participants (Anticipated)	Interventional	2022-02-02	Recruiting
Immunotherapy by Nivolumab in Neoadjuvant and Adjuvant Setting in Patients With Advanced HCC Treated by Electroporation in Curative Intent: French Multicenter Phase 2 Therapeutic Trial.[NCT03630640]	Phase 2	43 participants (Actual)	Interventional	2018-10-11	Active, not recruiting
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven: a Multi-center Randomized Controlled Trial.[NCT05171166]	Phase 2/Phase 3	156 participants (Anticipated)	Interventional	2021-12-24	Recruiting
Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy[NCT01308034]	Phase 1	25 participants (Actual)	Interventional	2011-03-31	Completed
A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Patients With Relapsed or Refractory Advanced Non-small Cell Lung Carcinoma[NCT00101413]	Phase 2	52 participants (Actual)	Interventional	2004-04-30	Completed
A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.[NCT00073307]	Phase 3	903 participants (Actual)	Interventional	2003-11-30	Completed
Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme[NCT00597493]	Phase 2	32 participants (Actual)	Interventional	2007-09-30	Completed
Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase[NCT00217646]	Phase 1	36 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized Phase 2 Trial of Double-Blind, Placebo Controlled AMG 706 in Combination With Paclitaxel, or Open-Label Bevacizumab in Combination With Paclitaxel, as First Line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cance[NCT00356681]	Phase 2	282 participants (Actual)	Interventional	2006-12-31	Terminated (stopped due to Sponsor decision to close study)
Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib[NCT02416739]	Phase 2/Phase 3	110 participants (Actual)	Interventional	2015-03-31	Active, not recruiting
A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007]	Phase 2/Phase 3	37 participants (Actual)	Interventional	2016-03-31	Completed
Longitudinal Immune-phenotyping of Surgically Resected HCC Following Neoadjuvant and Adjuvant Treatment With MK-3475[NCT04224480]	Phase 1	45 participants (Anticipated)	Interventional	2019-12-10	Recruiting
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme[NCT00445588]	Phase 2	56 participants (Actual)	Interventional	2007-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Disease-free survival (DFS) is defined as time from randomization to recurrence, development of second primary cancer (except localized breast or prostate cancer or nonmelanoma skin cancer), or death from any cause. Patients who were alive without recurrence or qualifying second primary cancer were censored at the date of last disease evaluation. 5-year DFS rate is the proportion of patients who are alive and disease-free at 5 years based on the Kaplan-Meier estimate. (NCT00326898)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry

5-year Overall Survival Rate

Intervention	proportion of participants (Number)
Arm A (Sunitinib + Sorafenib Placebo)	0.534
Arm B (Sorafenib + Sunitinib Placebo)	0.527
Arm C (Sunitinib Placebo + Sorafenib Placebo)	0.560

Overall survival is defined as the time from randomization to death from any cause. Patients without a date of death were censored at the date of last contact. Kaplan-Meier method was used to estimate 5-year survival rate. (NCT00326898)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry

Disease-free Survival (DFS)

Intervention	proportion of participants (Number)
Arm A (Sunitinib + Sorafenib Placebo)	0.779
Arm B (Sorafenib + Sunitinib Placebo)	0.805
Arm C (Sunitinib Placebo + Sorafenib Placebo)	0.803

Disease-free survival (DFS) is defined as time from randomization to recurrence, development of second primary cancer (except localized breast or prostate cancer or nonmelanoma skin cancer), or death from any cause. Patients who were alive without recurrence or qualifying second primary cancer were censored at the date of last disease evaluation. (NCT00326898)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry

Proportion of Patients With Cardiac Events

Intervention	years (Median)
Arm A (Sunitinib + Sorafenib Placebo)	5.8
Arm B (Sorafenib + Sunitinib Placebo)	6.1
Arm C (Sunitinib Placebo + Sorafenib Placebo)	6.6

Cardiac event is defined as left ventricular ejection fraction (LVEF) below the institutional lower limit of normal, where the decrease was >15% absolute percentage points from baseline within 6 months. (NCT00326898)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry

Phase I: Maximum Tolerated Dose (MTD) of Sorafenib Given With Azacitidine

Intervention	Proportion of participants (Number)
Arm A (Sunitinib + Sorafenib Placebo)	0.017
Arm B (Sorafenib + Sunitinib Placebo)	0.013
Arm C (Sunitinib Placebo + Sorafenib Placebo)	0.008

MTD is defined as highest dose level in which 6 patients treated with at most 1 experiencing a dose limiting toxicity (DLT) during 1st cycle. One cycle of therapy is 7 days of azacitidine (AZA) and 28 days of sorafenib. Starting dose of Sorafenib is 200 mg twice a day azacitidine (NCT01254890)
Timeframe: 28 day cycle

Phase II: Number of Participants With Response

Intervention	mg/twice daily (Number)
Azacitidine + Sorafenib	400

Response according to International Working Group response criteria for Acute myeloid leukemia (AML) (JCO 2003; 21: 4642-9): CR defined by presence of <5% blasts in the bone marrow (BM), with >1 X 10^9/L neutrophils and >100 x 10^9/L platelets in the peripheral blood (PB) with no detectable extramedullary disease. Participants who met the above criteria but had neutrophil or platelet counts less than the stated values were considered to have achieved CRi (CR with incomplete recovery of PB counts) or CR with incomplete platelet recovery (CRp) if CR but platelets < 100 x 10^9/L but ≥ 50 x 10^9/L and platelet transfusion independent. Partial response (PR) required all of the hematologic values for a CR but with a decrease of >/= 50% in the percentage of blasts to 5% to 25% in the BM aspirate. (NCT01254890)
Timeframe: 90 days

Overall Survival (OS)

Intervention	participants (Number)
	Complete Response (CR)	Complete Remission Without Platelet Recovery (CRi)	Partial Response	Complete Response (CRp)	No Response
Azacitidine + Sorafenib	8	10	1	6	23

"OS was defined as the time from randomization to date of death due to any cause. OS for subjects alive at the time of analysis was censored at their last date of contact. NA in the reported data indicates values could not be estimated due to censored data." (NCT00692770)
Timeframe: From randomization of the first subject until 4 years later.

Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Index Score

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	NA
Placebo	NA

The EQ-5D is a generic quality of life preference based on a validated instrument used in cancer and in general population, with 2 parts: Index and Visual Analogue Scale. The EQ-5D Index is a descriptive system of the following health dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. Subjects were asked to choose any one of the 3 response levels for each dimension: no problems, some problems, and severe problems. The 5 health dimensions were summarized into a single score, the EQ-5D Index score which ranged from -0.59 to 1 with higher scores representing better health states (0=death, 1= perfect health, and -0.59=a health state worse than death). A change of at least 0.10 to 0.12 points was considered a minimally important difference using Eastern Cooperative Oncology Group Performance Status as the anchor. The results on the Analysis of covariance of timeadjusted Area under curve for the EQ-5D index score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Visual Analogue Scale (VAS) Score

Intervention	Unit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)	0.827
Placebo	0.866

The EQ-5D is a generic quality of life preference based on a validated instrument used in cancer and in general population, with 2 parts: Index and Visual Analogue Scale. The EQ-5D VAS is a measure that represents health status as a single value. It is a 20-centimetre vertical graduated visual analogue scale with scores that ranged from 0 (worst imaginable health state) to 100 (best imaginable health state). The respondent rated his/her current health state by drawing a line from the box marked 'your own health state today' to the appropriate point on the EQ-5D VAS. A 3-digit number (including leading zeros) was read off the scale from the point where the respondent's line crossed the scale, which was the EQ-5D VAS score. A change of at least 7 points on the VAS was considered as minimally important. The results on the ANCOVA analysis of time-adjusted AUC for the EQ-5D VAS score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

Patient Reported Outcomes: Functional Assessment of Cancer Therapy (FACT)- General (G) Total Score

Intervention	Unit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)	77.203
Placebo	80.181

The PWB, FWB, SWB and EWB were summed to form the FACT-G total score. Subjects responded to each item on a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). FACT-G scores ranged from 0 to 108 and the higher scores represented a better quality of life. The MID for the FACT-G total score was in the range of 6 to 7. The results on the ANCOVA analysis of time-adjusted AUC for the FACT-G score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

Patient Reported Outcomes: Functional Assessment of Cancer Therapy (FACT)- Hepatobiliary Subscale (HEP) Score

Intervention	Unit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)	80.46
Placebo	82.95

The FACT-HEP is a 45 item, self-administered, multi-dimensional, psychometrically sound questionnaire used extensively in oncology clinical trials. FACT-HEP consisted of five subscales: Physical Well-Being (PWB), Social Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB), and Hepatobiliary Cancer Subscale (HCS). The PWB, FWB, SWB and EWB were summed to form the FACTGeneral (FACT-G) total score. The FACT-G and HCS scores were summed to form the FACT-HEP total score. FACT-HEP scores ranged from 0 to 180 and the higher scores represented a better quality of life. Subjects responded to each item on a 5-point Likert-type scale ranging from 0 (not at all) to 4 (very much). The minimally important difference (MID) for the FACT-Hep total score was in the range of 8 to 9. The results on the ANCOVA analysis of time-adjusted AUC for the FACT-HEP score were reported. (NCT00692770)
Timeframe: Cycle (C) Day (D)1, C2D1, C3D1 and subsequent cycles up to C18, end of intervention visit

Recurrence Free Survival (RFS) by Independent Assessment

Intervention	Unit on a scale (Least Squares Mean)
Sorafenib (Nexavar, BAY43-9006)	138.7
Placebo	143.79

Disease recurrence of HCC (intra or extra hepatic) was defined as the appearance of a new intrahepatic lesions fulfilling the American Association for the Study of Liver Diseases (AASLD) criteria of diagnosis of HCC or a new extra-hepatic lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. In addition to investigator assessment, all images were reviewed by an independent panel of radiologists. The calculation of the RFS was based on the independent evaluation of the scans. RFS was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment or death due to any cause whichever occurred first. For subjects who had not recurred or died at the time of analysis, RFS was censored at their last date of evaluable scan before drop-out for any other reason than recurrence or death. (NCT00692770)
Timeframe: From randomization up to 4 years or until disease recurrence whichever came first

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - AFP

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	1014
Placebo	1026

"Biomarker was analyzed at baseline [i.e., before treatment] as a dichotomized variable based on median biomarker levels, and dichotomized into high and low groups using an optimal max chi cut-off approach - not per intervention. As such, results were analyzed according to this stratification. Max-chi square methodology was used to search for the optimal cut point for dichotomization of each plasma biomarker and Kaplan-Meier curves were generated using the optimal cut point for each possible association examined. These biomarker analyses were retrospective and exploratory and of signal generating nature only." (NCT00692770)
Timeframe: At Baseline

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - ANG-2

Intervention	Days (Median)
AFP High Expression Group	668
AFP Low Expression Group	1267

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - MET

Intervention	Days (Median)
ANG-2 High Expression Group	588
ANG-2 Low Expression Group	1260

Time to Recurrence (TTR) by Independent Assessment

Intervention	Days (Median)
MET High Expression Group	841
MET Low Expression Group	NA

"TTR was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment. For subjects who had not recurred at the time of analysis, TTR was censored at their last date of evaluable scan before withdrawal for any other reason than recurrence. NA in the reported data indicates values could not be estimated due to censored data." (NCT00692770)
Timeframe: From randomization up to 4 years or until disease recurrence whichever came first

Duration of Stable Disease

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	1172
Placebo	1089

Duration of stable disease was calculated as date of first treatment until date of documented progressive disease (PD) or last observation if subject did not progress. Stable disease (SD) defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Kaplan-Meier methodology, descriptive analysis. (NCT00101413)
Timeframe: First patient first treatment until date for last data collection for efficacy for a study period up to 62 weeks. Tumor assessed per RECIST at baseline (BL), every 8 weeks during treatment and at end of treatment.

Overall Survival

Intervention	days (Median)
Sorafenib	103

"Overall survival was calculated from the date of the first treatment until death of the subject.~Evaluation by Kaplan-Meier methodology, descriptive analysis." (NCT00101413)
Timeframe: First patient first treatment until date for last data collection for efficacy for a study period up to 62 weeks.

Percentage of Subjects With Stable Disease (SD)

Intervention	days (Median)
Sorafenib	205

Percentage of subjects with stable disease was calculated from date of first treatment until date of documented progressive disease (PD) or last observation if subject did not progress. Stable disease (SD) defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Descriptive summary of subjects with SD. (NCT00101413)
Timeframe: First patient first treatment until date for last data collection for efficacy for a study period up to 62 weeks. Tumor assessed per RECIST at baseline (BL), every 8 weeks during treatment and at end of treatment.

Anti-cancer Activity (eg, Percentage of Patients With Confirmed Complete Responses (CR) and Partial Responses (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) Criteria in Patients With Stage IV Non-small Cell Lung Carcinoma (NSCLC)

Intervention	Percentage of participants (Number)
Sorafenib	58.8

CR-disappearance of clinical/radiological tumor evidence (target/nontarget). PR- >=30% decrease in sum longest diameter (LD) of target lesions from BL sum LD. Stable disease (SD)-no shrinkage for PR nor increase for PD. Progressive disease (PD) measurement proven- >=20% increase in sum LD of lesions from smallest sum LD since start or new lesions. Progression by clinical judgement- >clinically meaningful cancer-related deterioration as judged by the investigator. (NCT00101413)
Timeframe: First patient first treatment until date for last data collection for efficacy for a study period up to 62 weeks. Tumor assessed per RECIST at baseline (BL), every 8 weeks during treatment and at end of treatment.

Change From Baseline of Health-Related Quality of Life (HRQOL) Score Assessed at Cycle 2, Cycle 4, and End of Treatment (EOT)

Intervention	percentage of participants (Number)
	Complete response + Partial response	Complete response	Partial response	Stable disease	Progressive disease measurement proven	Progression by clinical judgement	Not evaluated
Sorafenib	0.0	0.0	0.0	58.8	23.5	11.8	5.9

HRQoL was assessed with the FACT-L questionnaire, a validated instrument for determining lung cancer HRQoL. The 36-item questionnaire includes 4 domains: Physical, functional, emotional, and social/family well-being, and a lung cancer-specific subscale. The FACT-L total score ranges from 1 to 136. Lower scores (negative change from baseline) demonstrate impaired HRQoL. (NCT00101413)
Timeframe: From first patient first treatment until date of last efficacy data collection (study period up to 62 weeks). HRQoL assessed at baseline (BL), end of treatment Cycles 2 and 4, and at end of treatment

Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population

Intervention	scores on a scale (Mean)
	Cycle 2	Cycle 4	End of treatment
Sorafenib	-4.8	0.0	-14.9

Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later

Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population

Intervention	days (Median)
Sorafenib (Nexavar, BAY43-9006)	542
Placebo	436

Final Progression-Free Survival (PFS) - Independent Radiological Review

Intervention	days (Median)
Sorafenib (Nexavar, BAY43-9006)	542
Placebo	461

PFS determined as the time (days) from the date of randomization at start of study to the actual date of disease progression (PD) (radiological or clinical) or death due to any cause, if death occurred before PD. Outcome measure was assessed approximately every 8 weeks using RECIST v1.0 criteria by independent radiologic review. Radiological PD defined as at least 20% increase in sum of longest diameter (LD) of measured lesions taking as reference smallest sum LD recorded since treatment started or appearance of new lesions. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.

Best Overall Response - Independent Radiological Review

Intervention	days (Median)
Sorafenib (Nexavar, BAY43-9006)	167
Placebo	84

Best overall response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 by independent radiologic review. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased) and not evaluated. (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.

Health-related Quality of Life (HRQOL) by FKSI-10 (Functional Assessment of General Therapy Kidney Symptom Index 10) Assessment

Intervention	percentage of participants (Number)
	Complete Response	Partial Response	Stable Disease	Progressive Disease	Not Evaluated
Placebo	0.0	0.0	55.2	30.3	14.5
Sorafenib (Nexavar, BAY43-9006)	0.0	2.1	77.9	8.7	11.3

"Primary Analysis for FKSI-10 patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FKSI-10 patient responses for each question range from 0=not at all to 4=very much and after reverse coding the range of values for FKSI-10 total score is from 0 to 40; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.

Health-related Quality of Life (HRQOL) by Physical Well-Being (PWB) Score of the FACT-G (Functional Assessment of Cancer Therapy-General Version) Assessment

Intervention	Scores on a scale (Least Squares Mean)
	Cycle 2, Day 1	Cycle 3, Day 1	Cycle 4, Day 1	Cycle 5, Day 1	Cycles 1-5 (Overall)
Placebo	27.78	27.28	26.78	26.28	27.20
Sorafenib (Nexavar, BAY43-9006)	27.77	27.27	26.77	26.27	27.19

"Primary Analysis for FACT-G (using PWB score) patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FACT-G (PWB score) patient responses for each question range from 0=not at all to 4=very much and after reverse coding the total FACT-G (PWB score) range of values is from 0 to 28; higher score represents better HRQOL." (NCT00073307)
Timeframe: From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.

6 Month Progression Free Survival (PFS)

Intervention	Scores on a scale (Least Squares Mean)
	Cycle 2, Day 1	Cycle 3, Day 1	Cycle 4, Day 1	Cycle 5, Day 1	Cycles 1-5 (Overall)
Placebo	21.16	20.72	20.28	19.84	20.65
Sorafenib (Nexavar, BAY43-9006)	21.21	20.77	20.33	19.89	20.70

Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. (NCT00597493)
Timeframe: 6 months

Pharmacokinetics: AUC-24

Intervention	percentage of patients (Number)
Sorafenib + Temozolomide	9.4

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Pharmacokinetics: C-max

Intervention	ug*H/L (Geometric Mean)
EIAEDs-Day 1	45309.7
EIAEDs-Day 28	47148.2
Non-EIAEDs-Day 1	45238.7
Non-EIAEDs-Day 28	128820.8

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. C-max refers to maximum plasma concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Pharmacokinetics: T-max

Intervention	ug/L (Geometric Mean)
EIAEDs-Day 1	3397.3
EIAEDs-Day 28	3813.9
Non-EIAEDs-Day 1	3155.1
Non-EIAEDs-Day 28	8118.8

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. T-max refers to time to maximum concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Safety and Toxicity of Combination

Intervention	hours (Median)
EIAEDs-Day 1	8.2
EIAEDs-Day 28	2.1
Non-EIAEDs-Day 1	24.0
Non-EIAEDs-Day 28	4.2

Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment. (NCT00597493)
Timeframe: 16 months

6months -Progression-free Survival Rate

Intervention	participants (Number)
Sorafenib + Temozolomide	19

defined patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up (NCT00445588)
Timeframe: At 6 months- defined as patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up

Overall Survival

Intervention	percentage of participants (Number)
Treatment	14

death. measured by time of first day of treatment until date of death, assessed up to 2 years. (NCT00445588)
Timeframe: Time of first day of the treatment to death, assessed up to 2 years

Article	Year
The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml. Nuklearmedizin. Nuclear medicine, 2022, Volume: 61, Issue:2 Topics: Aged; Aged, 80 and over; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Middle	2022
A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World journal of surgical oncology, 2021, Jun-10, Volume: 19, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Loca	2021
Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation. European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:15 Topics: Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm	2017
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2014, Volume: 20, Issue:3 Topics: Antineoplastic Agents; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Glucocorticoids; Graft Rej	2014
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014, Volume: 63, Issue:5 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Mod	2014
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014, Volume: 63, Issue:5 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Mod	2014
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014, Volume: 63, Issue:5 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Mod	2014
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014, Volume: 63, Issue:5 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Mod	2014
Sorafenib use in the transplant setting. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2014, Volume: 20, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Humans; Immunosuppressive	2014
Adjuvant therapy for hepatocellular carcinoma after curative treatment. Digestive diseases (Basel, Switzerland), 2014, Volume: 32, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoem	2014
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Ne	2015
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World journal of gastroenterology, 2015, Oct-07, Volume: 21, Issue:37 Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Disease Progression; DNA Methylation; Epige	2015
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World journal of gastroenterology, 2015, Oct-21, Volume: 21, Issue:39 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Ne	2015
Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature. Journal of cancer research and therapeutics, 2015, Volume: 11 Suppl 2 Topics: Antineoplastic Agents; Female; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Odds Ratio; Ph	2015
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget, 2016, Jun-07, Volume: 7, Issue:23 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic;	2016
[Oncology 2008]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:25-26 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2008
Current management of hepatocellular carcinoma. The Medical clinics of North America, 2009, Volume: 93, Issue:4 Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Ther	2009
[Current therapy for hepatocellular carcinoma]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:6 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Emboliza	2010
Classic biphasic pulmonary blastoma: a case report and review of the literature. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:2 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Fatal Outcome; Humans; Intestinal Pe	2011
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Medical molecular morphology, 2011, Volume: 44, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C	2011
Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology, 2011, Volume: 81 Suppl 1 Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy,	2011
Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. Transplant international : official journal of the European Society for Organ Transplantation, 2013, Volume: 26, Issue:2 Topics: Animals; Carcinoma, Hepatocellular; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transpl	2013
Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. Anti-cancer drugs, 2013, Volume: 24, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu	2013
ARCON--current status: summary of a workshop on preclinical and clinical studies. Acta oncologica (Stockholm, Sweden), 1997, Volume: 36, Issue:5 Topics: Animals; Carbon Dioxide; Cell Division; Cell Hypoxia; Head and Neck Neoplasms; Humans; Neoplasm Recu	1997

Article	Year
A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale. PloS one, 2022, Volume: 17, Issue:7 Topics: Edetic Acid; Gallium Radioisotopes; Humans; Ligands; Male; Neoplasm Recurrence, Local; Niacinamide;	2022
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade Gynecologic oncology, 2020, Volume: 156, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; MA	2020
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Nov-10, Volume: 35, Issue:32 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; D	2017
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 11-01, Volume: 28, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; He	2017
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. Digestive diseases (Basel, Switzerland), 2017, Volume: 35, Issue:6 Topics: Adult; Aged; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; L	2017
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood, 2013, Jun-06, Volume: 121, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Feasibi	2013
Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation. Anticancer research, 2013, Volume: 33, Issue:6 Topics: Adolescent; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms;	2013
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). Journal of hematology & oncology, 2013, Jul-05, Volume: 6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Large B-Cell, Diffu	2013
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-01, Volume: 19, Issue:17 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva	2013
A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-01, Volume: 19, Issue:23 Topics: Adolescent; Antineoplastic Agents; Area Under Curve; Bone Neoplasms; Child; Child, Preschool; Drug A	2013
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Investigational new drugs, 2014, Volume: 32, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma,	2014
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer medicine, 2014, Volume: 3, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Human	2014
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. Head & neck, 2016, Volume: 38, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head a	2016
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma. European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:2 Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therap	2015
Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors. Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:4 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female;	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; C	2015
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World journal of gastroenterology, 2016, Jun-21, Volume: 22, Issue:23 Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therap	2016
A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. Journal of neuro-oncology, 2016, Volume: 129, Issue:3 Topics: Adolescent; Alanine Transaminase; Antineoplastic Agents; Blood Cell Count; Central Nervous System Ne	2016
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. European journal of cancer (Oxford, England : 1990), 2016, Volume: 69 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepider	2016
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-01, Volume: 27, Issue:19 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free S	2009
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Resis	2009
Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5 Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Re	2010
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecologic oncology, 2010, Volume: 117, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinosarcoma;	2010
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Journal of neuro-oncology, 2011, Volume: 101, Issue:1 Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bra	2011
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Femal	2010
Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm;	2010
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica, 2011, Volume: 96, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Female; Humans; Leukemia, Lymphocytic, Chronic, B	2011
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-01, Volume: 29, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Fem	2011
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. The Lancet. Oncology, 2011, Volume: 12, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem	2011
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Neop	2012
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2012, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Di	2012
[Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:9 Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re	2011
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro-oncology, 2011, Volume: 13, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progress	2011
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecologic oncology, 2011, Volume: 123, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relati	2011
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. Urologic oncology, 2013, Volume: 31, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease	2013
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. International journal of radiation oncology, biology, physics, 2013, Feb-01, Volume: 85, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell	2013
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blin	2013
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-oncology, 2012, Volume: 14, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Femal	2012
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv	2013
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecologic oncology, 2013, Volume: 129, Issue:1 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; DNA, Neoplasm; Fallopian Tube Neoplasms; Female; G	2013
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-oncology, 2013, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; E	2013
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relati	2006
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-01, Volume: 13, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell L	2007
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-20, Volume: 25, Issue:24 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease Progression	2007

Article	Year
Comparing the clinical performance and cost efficacy of [ European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:12 Topics: Decision Support Techniques; Edetic Acid; Fluorine Radioisotopes; Gallium Isotopes; Gallium Radioiso	2022
Potential Pitfall in the Interpretation of Ganglioneuronal Uptake of 18 F-PSMA-1007 PET/CT Scans Performed With a High Spatial Resolution Digital PET Scanner. Clinical nuclear medicine, 2022, Sep-01, Volume: 47, Issue:9 Topics: Aged; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Neoplasm Recurrence, Local	2022
Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml. Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:2 Topics: Aged; Aged, 80 and over; Fluorine Radioisotopes; Follow-Up Studies; Humans; Male; Middle Aged; Neopl	2020
High detection rate in [ Annals of nuclear medicine, 2021, Volume: 35, Issue:4 Topics: Aged; Bone Neoplasms; Diagnostic Imaging; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm R	2021
Concurrent carbogen and nicotinamide with radiation therapy in muscle invasive bladder cancer: A report on feasibility in the Australian setting. Journal of medical imaging and radiation oncology, 2021, Volume: 65, Issue:6 Topics: Aged; Australia; Carbon Dioxide; Feasibility Studies; Humans; Muscles; Neoplasm Recurrence, Local; N	2021
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry. American journal of surgery, 2017, Volume: 213, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Tr	2017
Double trouble for CML. Science translational medicine, 2017, 04-05, Volume: 9, Issue:384 Topics: Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurre	2017
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index. Advances in therapy, 2017, Volume: 34, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization,	2017
Management of hepatocellular carcinoma recurrence after liver transplant is far from perfect. American journal of surgery, 2018, Volume: 216, Issue:2 Topics: Adult; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Re	2018
Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers. Oncogene, 2017, 10-05, Volume: 36, Issue:40 Topics: Animals; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhib	2017
Desmoid Tumors and Celecoxib with Sorafenib. The New England journal of medicine, 2017, 06-29, Volume: 376, Issue:26 Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female	2017
Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor: Analysis of a preliminary experience on 15 consecutive cases. Medicine, 2017, Volume: 96, Issue:29 Topics: Adult; Aged; Antineoplastic Agents; Blood Vessel Prosthesis; End Stage Liver Disease; Female; Hepate	2017
Liver resection for hepatocellular carcinoma in patients with hematological malignancies. World journal of surgical oncology, 2017, Nov-02, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellul	2017
Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy. Clinical genitourinary cancer, 2018, Volume: 16, Issue:2 Topics: Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; N	2018
[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. Clinical genitourinary cancer, 2018, Volume: 16, Issue:2 Topics: Arthroplasty; Fluorine Radioisotopes; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local	2018
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. Radiology, 2018, Volume: 287, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization,	2018
Advantage of European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:6 Topics: Edetic Acid; Fluorine Radioisotopes; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Neoplasm	2018
Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007. Clinical nuclear medicine, 2019, Volume: 44, Issue:6 Topics: Fluorine Radioisotopes; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Oligopep	2019
[Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib]. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:3 Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Recu	2019
18F-Prostate-Specific Membrane Antigen 1007 and 18F-FCH PET/CT in Local Recurrence of Prostate Cancer. Clinical nuclear medicine, 2019, Volume: 44, Issue:6 Topics: Aged; Choline; Fluorine Radioisotopes; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Oligop	2019
Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2013, Volume: 19, Issue:5 Topics: Animals; Apoptosis; Disease Models, Animal; Disease-Free Survival; Extracellular Signal-Regulated MA	2013
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:2 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Res	2013
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. Journal of hepatology, 2013, Volume: 59, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Coh	2013
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence. Journal of hepatology, 2013, Volume: 59, Issue:1 Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re	2013
Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling. Molecular cancer therapeutics, 2013, Volume: 12, Issue:9 Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Cyclin G1; Drug Resistan	2013
Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma. Future oncology (London, England), 2013, Volume: 9, Issue:8 Topics: Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Neoplasms	2013
[Complete remission by sorafenib for local reccurence of renal cell carcinoma with a tempraly elevation of C-reactive protein: a case report]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2013, Volume: 104, Issue:4 Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Ma	2013
Reply to: "Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma". Journal of hepatology, 2014, Volume: 60, Issue:1 Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re	2014
Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma. Journal of hepatology, 2014, Volume: 60, Issue:1 Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re	2014
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. Langenbeck's archives of surgery, 2013, Volume: 398, Issue:8 Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; L	2013
Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. Cancer biology & therapy, 2014, Volume: 15, Issue:1 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence,	2014
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:1 Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Clofarabine; Cytarabine; Female; fms-Like Tyrosine K	2014
Reply to: "Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue". Journal of hepatology, 2014, Volume: 60, Issue:3 Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re	2014
Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue. Journal of hepatology, 2014, Volume: 60, Issue:3 Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Re	2014
Multi-kinase inhibition in ovarian cancer. Cancer biology & therapy, 2014, Volume: 15, Issue:1 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Niaci	2014
Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study. Anti-cancer drugs, 2014, Volume: 25, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Middle Aged; Neop	2014
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation, 2014, Jul-15, Volume: 98, Issue:1 Topics: Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Ad	2014
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:7 Topics: Adenocarcinoma, Follicular; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phen	2014
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity? European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Interactions; Everolimus; Humans; Immunosuppr	2014
(99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer. Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:8 Topics: Animals; Cattle; Cell Differentiation; Cell Separation; CHO Cells; Cricetinae; Cricetulus; Dogs; Flo	2014
Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma. Anti-cancer drugs, 2014, Volume: 25, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Ni	2014
Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. British journal of haematology, 2014, Volume: 167, Issue:1 Topics: Antineoplastic Agents; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasm R	2014
Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study. The American surgeon, 2014, Volume: 80, Issue:7 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neopl	2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. The Journal of urology, 2015, Volume: 193, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols	2015
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta neuropathologica, 2014, Volume: 128, Issue:6 Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Co	2014
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. Molecular medicine reports, 2015, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulati	2015
Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World journal of gastroenterology, 2014, Oct-21, Volume: 20, Issue:39 Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male	2014
Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib. Oncology, 2015, Volume: 88, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Dr	2015
The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells. Breast cancer research and treatment, 2015, Volume: 149, Issue:3 Topics: Animals; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation;	2015
Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. Bioscience trends, 2014, Volume: 8, Issue:6 Topics: Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Liver	2014
A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:9 Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatectomy; Hepatitis	2015
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors. Journal of pediatric surgery, 2015, Volume: 50, Issue:9 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Fe	2015
Sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a report of four cases. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 65, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplanta	2015
NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Leukemia, 2015, Volume: 29, Issue:7 Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cyclosporine; Drug Resistance,	2015
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma. Yonsei medical journal, 2015, Volume: 56, Issue:5 Topics: Aged; Antineoplastic Agents; Ascorbic Acid; Carcinoma, Hepatocellular; Chemoembolization, Therapeuti	2015
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. Archives of endocrinology and metabolism, 2015, Volume: 59, Issue:4 Topics: Aged; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinami	2015
Targeted therapy for advanced or metastatic differentiated thyroid carcinoma. Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:4 Suppl 4 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasm Recur	2015
Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival. Clinical transplantation, 2015, Volume: 29, Issue:12 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combined Modality Therapy; Foll	2015
Nicotinamide yields impressive results in skin cancer. The Lancet. Oncology, 2015, Volume: 16, Issue:16 Topics: Administration, Oral; Anticarcinogenic Agents; Humans; Neoplasm Recurrence, Local; Niacinamide; Rand	2015
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clinical and molecular hepatology, 2015, Volume: 21, Issue:3 Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular	2015
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. BMC cancer, 2016, Jan-19, Volume: 16 Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutati	2016
Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia. Journal of pediatric hematology/oncology, 2016, Volume: 38, Issue:3 Topics: Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Ne	2016
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. Journal of hematology & oncology, 2016, Mar-08, Volume: 9 Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;	2016
Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML. Annals of hematology, 2016, Volume: 95, Issue:6 Topics: Alopecia; Antineoplastic Agents; Child, Preschool; Female; Humans; Leukemia, Myeloid, Acute; Lymphoc	2016
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. Oncotarget, 2016, Jul-05, Volume: 7, Issue:27 Topics: Adult; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival;	2016
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World journal of gastroenterology, 2016, Apr-21, Volume: 22, Issue:15 Topics: Administration, Oral; Adult; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression;	2016
Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. BMC cancer, 2016, 05-31, Volume: 16 Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver	2016
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation. World journal of gastroenterology, 2016, Jul-07, Volume: 22, Issue:25 Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Liver Neopl	2016
[Prediction and preventive strategies for recurrence after surgery for hepatocellular carcinoma]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016, May-20, Volume: 24, Issue:5 Topics: Biopsy; Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Immunotherapy; Interferons; Li	2016
Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation. Progress in transplantation (Aliso Viejo, Calif.), 2016, Volume: 26, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Ne	2016
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma. BMC cancer, 2016, 08-24, Volume: 16 Topics: Antineoplastic Agents; Chordoma; Graves Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Neopl	2016
Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget, 2016, Dec-13, Volume: 7, Issue:50 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distrib	2016
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Trials, 2016, 11-25, Volume: 17, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disea	2016
18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. Clinical genitourinary cancer, 2017, Volume: 15, Issue:3 Topics: Aged; Fluorine Radioisotopes; Humans; Male; Neoplasm Micrometastasis; Neoplasm Recurrence, Local; Ni	2017
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Gynecologic oncology, 2017, Volume: 145, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors	2017
Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma. Anticancer research, 2017, Volume: 37, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Feasibility Studie	2017
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Sur	2009
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. European urology, 2009, Volume: 55, Issue:6 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dose-	2009
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer control : journal of the Moffitt Cancer Center, 2009, Volume: 16, Issue:1 Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined C	2009
[Prospect of hepatocellular carcinoma in 2008]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2009, Volume: 17, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diagnosis, Differential; Humans	2009
Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer, 2009, Oct-15, Volume: 115, Issue:20 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Protocols; Humans; Li	2009
Hepatocellular carcinoma: the search for innovative adjuvant therapies. Oncology (Williston Park, N.Y.), 2009, Volume: 23, Issue:14 Topics: Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Carcinoma, Hepatocellular; Chemotherapy,	2009
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. Journal of hepatology, 2010, Volume: 52, Issue:5 Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; beta Catenin; Carcin	2010
Sorafenib plus valproic acid for infant spinal glioblastoma. Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Extrac	2010
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Japanese journal of clinical oncology, 2010, Volume: 40, Issue:8 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Dru	2010
Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver	2011
Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:1 Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Diagnostic Imaging; Humans; Immunosuppressive Agents;	2011
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation. Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Humans; Li	2010
Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib. Journal of clinical gastroenterology, 2011, Volume: 45, Issue:8 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; F	2011
Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Administration Sched	2010
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta pharmacologica Sinica, 2010, Volume: 31, Issue:12 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Thera	2010
mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. Journal of hepatology, 2011, Volume: 54, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Combin	2011
Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line,	2011
[Squamous cell carcinoma in a patient receiving sorafenib]. Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:2 Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; C	2011
Nicotinamide inhibits the early stage of carcinogen-induced hepatocarcinogenesis in mice and suppresses human hepatocellular carcinoma cell growth. Journal of cellular physiology, 2012, Volume: 227, Issue:3 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Disease Models, Animal; Di	2012
Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:9 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Gastrointestinal	2011
An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:8 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Growth Processes; Cell Li	2011
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Im	2012
Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms	2012
Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. Pediatric blood & cancer, 2012, Volume: 59, Issue:5 Topics: alpha-Fetoproteins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agent	2012
Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma. Journal of gastrointestinal cancer, 2012, Volume: 43 Suppl 1 Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Fo	2012
[Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation]. Zhonghua yi xue za zhi, 2012, May-15, Volume: 92, Issue:18 Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms;	2012
Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. Transplantation proceedings, 2012, Volume: 44, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplanta	2012
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemo	2012
Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients. Current oncology reports, 2007, Volume: 9, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm	2007
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU international, 2008, Volume: 102, Issue:6 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kid	2008
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. The Journal of urology, 2008, Volume: 180, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A	2008
Combination of fractionated irradiation with nicotinamide and carbogen in R1H-tumours of the rat and its pulmonary metastases. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1997, Volume: 45, Issue:2 Topics: Animals; Carbon Dioxide; Combined Modality Therapy; Disease Models, Animal; Dose Fractionation, Radi	1997
Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1998, Volume: 48, Issue:2 Topics: Actuarial Analysis; Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over	1998

niacinamide and Local Neoplasm Recurrence

Research Excerpts

Research

Studies (174)

Authors

Clinical Trials (26)

Trial Overview

Trial Outcomes

5-year Disease-free Survival (DFS) Rate Among Patients With Clear Cell Histology

5-year Overall Survival Rate

Disease-free Survival (DFS)

Proportion of Patients With Cardiac Events

Phase I: Maximum Tolerated Dose (MTD) of Sorafenib Given With Azacitidine

Phase II: Number of Participants With Response

Overall Survival (OS)

Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Index Score

Patient Reported Outcomes: Euroqol-5 Dimensions (EQ-5D) - Visual Analogue Scale (VAS) Score

Patient Reported Outcomes: Functional Assessment of Cancer Therapy (FACT)- General (G) Total Score

Patient Reported Outcomes: Functional Assessment of Cancer Therapy (FACT)- Hepatobiliary Subscale (HEP) Score

Recurrence Free Survival (RFS) by Independent Assessment

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - AFP

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - ANG-2

The Correlation Between Plasma Biomarker Levels at Baseline With RFS to Determine Prognostic Value of Biomarkers - MET

Time to Recurrence (TTR) by Independent Assessment

Duration of Stable Disease

Overall Survival

Percentage of Subjects With Stable Disease (SD)

Anti-cancer Activity (eg, Percentage of Patients With Confirmed Complete Responses (CR) and Partial Responses (PR) Per RECIST (Response Evaluation Criteria in Solid Tumors) Criteria in Patients With Stage IV Non-small Cell Lung Carcinoma (NSCLC)

Change From Baseline of Health-Related Quality of Life (HRQOL) Score Assessed at Cycle 2, Cycle 4, and End of Treatment (EOT)

Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population

Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population

Final Progression-Free Survival (PFS) - Independent Radiological Review

Best Overall Response - Independent Radiological Review

Health-related Quality of Life (HRQOL) by FKSI-10 (Functional Assessment of General Therapy Kidney Symptom Index 10) Assessment

Health-related Quality of Life (HRQOL) by Physical Well-Being (PWB) Score of the FACT-G (Functional Assessment of Cancer Therapy-General Version) Assessment

6 Month Progression Free Survival (PFS)

Pharmacokinetics: AUC-24

Pharmacokinetics: C-max

Pharmacokinetics: T-max

Safety and Toxicity of Combination

6months -Progression-free Survival Rate

Overall Survival

Reviews

Trials

Other Studies